Colin Bristow

Stock Analyst at UBS

(0)
# 4656
Out of 5,245 analysts
87
Total ratings
25.00%
Success rate
-17.77%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
Pfizer
Maintains: Neutral
31 29
26.29 10.31% 8 Jan 8, 2025
Merck & Co
Maintains: Buy
125 120
98.01 22.44% 6 Jan 8, 2025
PTC Therapeutics
Maintains: Strong Buy
47 71
43.96 61.51% 3 Dec 3, 2024
Gilead Sciences
Maintains: Neutral
70 96
91.83 4.54% 3 Nov 21, 2024
Vertex Pharmaceutica...
Maintains: Strong Buy
562 586
422 38.86% 13 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
335 326
272.23 19.75% 7 Oct 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
234 202
140.6 43.67% 10 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
25 4
1.74 129.89% 4 Aug 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
14 6
1.65 263.64% 3 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 41
23.86 71.84% 5 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
4 1
0.34 194.12% 5 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1090 1099
681.92 61.16% 1 Apr 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
7.04 425.57% 1 Mar 28, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
56 54
10.3 424.27% 2 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
164 167
117.92 41.62% 5 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
428 420
726.05 -42.15% 1 Dec 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
12 2
9.34 -78.59% 2 Dec 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
1.66 984.34% 1 Oct 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
154 146
171.41 -14.82% 2 Aug 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
73 75
56.34 33.12% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
64 26
3.93 561.58% 1 Apr 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
9
6.68 34.73% 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
195
n/a n/a 2 Feb 1, 2021